15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Eton Pharmaceuticals Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $62.00 to $70.00, so the covering firms are broadly aligned. The average target of $67.50 sits 14% above the current $59.42. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.43 next quarter toward $2.58 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Eton Pharmaceuticals Inc.
As of Sep, 4 of 4 firms rate ETON a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ETON EPS & revenue forecast
EPS · NEXT QUARTER
$0.43
Range $0.37 – $0.50 · 2 analysts · +129% YoY
Next period, 2 analysts expect Eton Pharmaceuticals Inc to earn $0.43 a share (range $0.37 – $0.50), versus $0.19 a year earlier. Full-year consensus is $1.40, growing to $2.58 the year after.
REVENUE · NEXT QUARTER
$45.9M
Range $44.4M – $47.5M · 2 analysts · +116% YoY
Revenue is expected to reach $45.9M (range $44.4M – $47.5M), +115.5% year-over-year. Full-year consensus is $149.7M, rising to $219.9M next year.
Top analysts covering Eton Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ETON.
#1
Chase Knickerbocker
Craig-Hallum · Rank #19
Buy
$62.00+4.3% to target
Overall win rate
61%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$70.00+17.8% to target
Overall win rate
38%
+ Follow
#3
ME
Madison El-Saadi
B. Riley Securities
Buy
$70.00+17.8% to target
Coverage
—
+ Follow
#4
GN
Gary Nachman
Canaccord Genuity
Buy
$68.00+14.4% to target
Coverage
—
+ Follow
ETON stock forecast FAQ
What is ETON's average 12-month price target?+
The 4 analysts with a live target average $67.50 for Eton Pharmaceuticals Inc over the next 12 months, ranging from a $70.00 high to a $62.00 low.
Is ETON stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ETON?+
The Street-high target is $70.00 (B. Riley Securities), and the Street-low is $62.00 (Craig-Hallum). The average of all 4 active targets is $67.50.
How many Wall Street analysts cover ETON?+
4 analysts have an active rating on Eton Pharmaceuticals Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ETON?+
Among analysts who currently cover ETON, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #19). Their current call is Buy with a $62.00 target.
What is Eton Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.43 per share (range $0.37 – $0.50) across 2 analysts. Full-year EPS is projected at $1.40, rising to $2.58 the following year.
How much revenue is Eton Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $45.9M (range $44.4M – $47.5M). Full-year revenue is projected at $149.7M, growing to $219.9M next year.
Have analysts been upgrading or downgrading ETON lately?+
As of Sep, 4 of 4 firms rate ETON a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ETON calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
